Remyelination plays an important role in determining the fate of
demyelinating disorders. However, it is arrested during
chronic disease states.
Cystatin F, a
papain-like lysosomal
cysteine proteinase inhibitor, is a crucial regulator of
demyelination and remyelination. Using hemizygous proteolipid
protein transgenic 4e (PLP4e/- ) mice, an animal model of chronic
demyelination, we found that
cystatin F
mRNA expression was induced at 2.5 months of age and up-regulated in the early phase of
demyelination, but significantly decreased in the chronic phase. We next investigated
cystatin F regulatory factors as potential mechanisms of remyelination arrest in chronic
demyelinating disorders. We used the CysF-STOP-tetO::Iba-
mtTA mouse model, in which
cystatin F gene expression is driven by the
tetracycline operator. Interestingly, we found that forced
cystatin F
mRNA over-expression was eventually decreased. Our findings show that
cystatin F expression is modulated post-transcriptionally. We next identified embryonic lethal, abnormal vision, drosophila like
RNA-binding protein 1 (ELAVL-1), and miR29a as
cystatin F
mRNA stabilizing and destabilizing factors, respectively. These roles were confirmed in vitro in NIH3T3 cells. Using postmortem plaque samples from human
multiple sclerosis patients, we also confirmed that ELAVL-1 expression was highly correlated with the previously reported expression pattern of
cystatin F. These data indicate the important roles of ELAVL-1 and miR29a in regulating
cystatin F expression. Furthermore, they provide new insights into potential therapeutic targets for
demyelinating disorders.